Philadelphia researchers at the University of Pennsylvania, working with engineers at Harvard, have wired up lab-grown mini pancreases with hair-thin electronics, nudging immature alpha and beta cells to grow up, synchronize and respond to sugar more like natural islets. The so-called "cyborg" mesh becomes part of the tissue as it forms, which lets the team run months of single-cell electrical monitoring and patterned stimulation that boosts glucose-triggered hormone release. The work, published in Science on Feb. 19, 2026, points toward new ways to prepare or support cell-based transplants for people with Type 1 diabetes.
Stretchy Electronics That Grow With the Tissue
The device is an ultrathin, stretchable mesh that researchers slide between layers of developing cells so it can flex with the expanding pancreatic organoid and record activity at single-cell resolution. According to Penn Medicine, the mesh is thinner than a human hair and can both pick up electrical spikes and deliver controlled pulses that simulate natural physiological rhythms. With that tight integration, scientists can follow how the tissue matures over weeks and step in with targeted electrical nudges without shredding the fragile organoids in the process.
Meal-Time Rhythms and Electrically Tuned Maturation
By cycling glucose levels to mimic meal-time rhythms, the team found that immature cells locked into circadian-like electrical patterns, which sharpened hormone release when the organoids were hit with glucose challenges. As outlined by Harvard SEAS, the researchers also tapped the implant's built-in actuators to deliver patterned stimulation that enhanced glucose responsiveness in stem-cell-derived alpha and beta cells. The peer-reviewed paper in Science reports months-long, single-cell recordings that line up with increased expression of genes tied to energy metabolism, cell-cell communication and exocytosis, along with improved electrical states.
Translational Paths: Prep the Cells or Leave the Mesh In
Juan Alvarez, an assistant professor at Penn, described the device as "bionic" and said that "the words 'bionic', 'cybernetic', 'cyborg', all of those apply to the device we've created," comparing its role to a pacemaker for pancreatic tissue. According to Penn Medicine, the team is eyeing two main paths: using electrical entrainment to pre-condition lab-grown islets before transplant, or leaving the sensors in place to monitor and stimulate grafts after implantation. The researchers say they still need to test long-term safety, durability and immune compatibility in preclinical models before anything moves toward human use.
Paper Details and Funding
The Science paper lists Qiang Li and Ren Liu as co-first authors and Jia Liu and Juan R. Alvarez-Dominguez as co-senior authors, with affiliations at Harvard SEAS and the Perelman School of Medicine. The PubMed record notes support from NIH grants, JDRF and the JPB Foundation, among other funders. As the authors move toward preclinical testing, they and their backers say they will focus on whether the approach can scale to human-grade grafts and how a bioelectronic scaffold holds up under immune pressure and long-term use.
